Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9121354 | 0.92 | LTB4R (0.48) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL9120017 | 0.92 | LTB4R (0.41) | LTB4RLTB4R2MEN1KMT2ACYP2C9 | |
| SCHEMBL9120026 | 0.90 | MEN1 (0.45) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL9121601 | 0.87 | LTB4R (0.46) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL9120015 | 0.87 | LTB4R (0.46) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL8463851 | 0.87 | LTB4R (0.44) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL8799251 | 0.87 | LTB4R (0.42) | LTB4RLTB4R2MEN1KMT2ACYP2C9 | |
| SCHEMBL9120964 | 0.87 | LTB4R (0.46) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL8799585 | 0.87 | LTB4R (0.43) | LTB4RLTB4R2MEN1KMT2A | |
| SCHEMBL9122251 | 0.86 | MEN1 (0.47) | LTB4RLTB4R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0755381-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B 4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028386-A1 | SUBSTITUTED PYRIDINE LEUKOTRIENE B4 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-10-26 | — | — | WO | disclosed |